Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia

被引：0
作者：
Yongzhi Zheng
Lili Pan
Jian Li
Xiaoqin Feng
Chunfu Li
Mincui Zheng
Huirong Mai
Lihua Yang
Yingyi He
Xiangling He
Honggui Xu
Hong Wen
Shaohua Le
机构：
[1] Fujian Institute of Hematology,Department of Pediatric Hematology
[2] Fujian Provincial Key Laboratory On Hematology,Department of Pediatrics
[3] Fujian Medical University Union Hospital,Department of Pediatric Hematology/Oncology, Hematology and Oncology
[4] Nanfang Hospital,Department of Pediatric Hematology/Oncology
[5] Southern Medical University,Department of Pediatrics
[6] Nanfang-Chunfu Children’s Institute of Hematology & Oncology,Department of Pediatric Hematology/Oncology
[7] TaiXin Hospital,undefined
[8] Hunan Children’s Hospital,undefined
[9] Shenzhen Children’s Hospital,undefined
[10] Zhujiang Hospital of Southern Medical University,undefined
[11] Guangzhou Women and Children’s Medical Center,undefined
[12] People’s Hospital of Hunan Province,undefined
[13] Sun Yat-Sen Memorial Hospital,undefined
[14] The First Affiliated Hospital of Xiamen University,undefined
来源：
BMC Cancer | / 24卷
关键词：
Pediatric acute myeloid leukemia; Minimal residual disease; Multiparametric flow cytometry; Prognostic value;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 190 条
[1]  
Reinhardt D(2022)Pediatric acute myeloid leukemia-past, present, and future J Clin Med 11 504-447
[2]  
Antoniou E(2017)Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood 129 424-293
[3]  
Waack K(2018)Clinical challenges in de novo pediatric acute myeloid leukemia Expert Rev Anticancer Ther 18 277-1766
[4]  
Döhner H(2018)Minimal/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: A clinical viewpoint and perspectives Int J Mol Sci 19 3492-315
[5]  
Estey E(2014)Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia Pediatr Blood Cancer 61 1761-552
[6]  
Grimwade D(2011)Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate J Clin Oncol 29 310-3632
[7]  
Amadori S(2010)Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial Lancet Oncol 11 543-1588
[8]  
Appelbaum FR(2012)Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia J Clin Oncol 30 3625-489
[9]  
Büchner T(2012)Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group Blood 120 1581-1199
[10]  
Klein K(2019)Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies Front Pediatr 7 412-126
12345678910